3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Colorectal Neoplasms
49
Rectal Neoplasms
32
Pancreatic Neoplasms
28
Colonic Neoplasms
24
Stomach Neoplasms
19
Neoplasm Metastasis
15
Neoplasms
13
Esophageal Neoplasms
10
Breast Neoplasms
7
Head and Neck Neoplasms
6
Recurrence
5
Lung Neoplasms
5
Carcinoma, Non-Small-Cell Lung
5
Adenocarcinoma Of Esophagus
5
Lymphoma, Large B-Cell, Diffuse
4
Carcinoma, Hepatocellular
4
Ovarian Neoplasms
3
Lymphoma, Extranodal NK-T-Cell
3
Liver Neoplasms
3
Gastrointestinal Neoplasms
3
Gallbladder Neoplasms
3
Fallopian Tube Neoplasms
3
Cholangiocarcinoma
3
Adenocarcinoma
3
Unspecified Adult Solid Tumor, Protocol Specific
2
Precursor Cell Lymphoblastic Leukemia-Lymphoma
2
Peritoneal Neoplasms
2
Myelodysplastic Syndromes
2
Melanoma
2
Lymphoma, Non-Hodgkin
2
Interventions
umbralisib
1
ublituximab
1
marizomib
1
fludarabine phosphate
1
fludarabine
1
enzastaurin
1
durvalumab
1
carotuximab
1
brigatinib
1
binimetinib
1
axicabtagene ciloleucel
1
Zoledronic Acid
1
Vitamin D
1
Receptors, Interleukin-6
1
Oxaliplatin
1
Leucovorin
1
Irinotecan
1
Interleukin 1 Receptor Antagonist Protein
1
Gemcitabine
1
Folfox protocol
1
Fluorouracil
1
Cyclophosphamide
1
Cisplatin
1
Calcium
1
Bevacizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
Disease Progression
×
Oxaliplatin
×
Clear all
NCT05712356
2026-05-26
BOLSTER
Lisata Therapeutics, Inc.
Phase 2
Terminated
66 enrolled
12 charts